Navigation Links
Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency
Date:9/21/2009

EMERYVILLE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that on September 15, 2009, the company received a letter from NASDAQ stating that, for the last 30 consecutive business days, the bid price of its common stock has closed below the minimum $1.00 per share requirement for continued listing on the NASDAQ Capital Market. The letter further stated that the company has been provided a period of 180 calendar days, or until March 15, 2010, to regain compliance. If, at anytime before March 15, 2010, the bid price of the common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, NASDAQ has indicated that it will provide written notification that compliance has been regained.

The deficiency letter has no effect on the listing of the company's common stock at this time and its common stock will continue to trade on the NASDAQ Capital Market under the symbol "BNVI."

In the event the Company does not regain compliance with the rule prior to the expiration of the period, it will receive written notification that its securities are subject to delisting. Alternatively, the Company may be eligible for an additional grace period if it meets the initial listing standards, with exception of bid price, for the NASDAQ Capital Market. If it meets the initial listing criteria, NASDAQ staff will notify the Company that it has been granted an additional 180 calendar day compliance period.

Bionovo intends to use its best efforts to regain compliance with NASDAQ's minimum bid requirement.

For further information on the relevant NASDAQ rules, please consult NASDAQ Listing Rules 5550(a)(2) - bid price, 5810(c)(3)(A) - grace period, 5810(b) - public disclosure, and 5505 - Capital Market criteria.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources, which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes it has discovered new classes of drug candidates within its rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and its stock is traded on the NASDAQ Capital Market under the symbol "BNVI". For more information about Bionovo and its programs, visit www.bionovo.com.

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general, our ability to raise additional capital to fund our operations, and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated, or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, including, without limitation, our registration statement on Form S-1 filed with the Securities and Exchange Commission on September 10, 2009, which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community
2. Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
3. Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference
4. Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
5. Bionovo, Inc. to Announce First Quarter Fiscal Year 2009 Financial Results on Thursday, May 7, 2009
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. Bionovo to Present at Wall Street Analyst Forums 20th Annual Institutional Investor Conference
8. Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009
9. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
10. Bionovo Announces Presentation at the National Cancer Institute
11. Bionovo Announces Cost Control Measures Taken
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical ... York, NY, on December 3rd, to benefit Holy Name Medical Center's programs and ... which raised over $1 million - the largest event in the Center's history, ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has ... report to their offering. ... This report analyzes the worldwide markets for Endodontic ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are provided for ...
(Date:12/8/2016)... Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento de produto ... gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor Jun ... , , ...
Breaking Medicine Technology: